Download PDF
Horm Metab Res 2004; 36(1): 1-6
DOI: 10.1055/s-2004-814200
Review
© Georg Thieme Verlag Stuttgart · New York

Co-activation of Platelets by Prolactin or Leptin - Pathophysiological Findings and Clinical Implications

H.  Wallaschofski1 , A.  Kobsar2 , O.  Sokolova2 , M.  Eigenthaler2 , T.  Lohmann1
  • 1Department of Internal Medicine I, University of Erlangen
  • 2Institute of Clinical Biochemistry, University of Wuerzburg, Germany
Further Information

Publication History

Received 8 May 2003

Accepted after revision 18 August 2003

Publication Date:
25 February 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Platelet activation is involved in the pathogenesis of atherosclerosis and venous thromboembolism, and might therefore be a possible link between the two entities. Prolactin and leptin have recently been recognized as potent co-activators of ADP-dependent platelet aggregation or P-selectin expression, and are therefore suspected as additional risk factors for both arterial and venous thrombosis. There are clinical situations that have a known association with higher prolactin or leptin levels (pregnancy, obesity or anti-psychotic therapy) and increased risk of thromboembolic events. We compared the impact of both hormones on platelet activation in vitro and in vivo, indicating that prolactin has a stronger effect on platelet activation as leptin in vitro and in vivo. We have also demonstrated that prolactin levels are increased in so called idiopathic thrombosis, and that conversely, patients with prolactinoma have an increased frequency of thrombosis during the hyperprolactinemic state, in a retrospective analysis. Moreover, we have demonstrated increased prolactin values in stroke and myocardial infarction. Prospective studies have yet to be performed to give this theory its final confirmation. The involvement of hormonal factors in platelet aggregation and venous or arterial thrombosis may have important clinical implications such as for risk stratification of patients with venous and arterial thrombosis or new therapeutic options such as decreasing pro-coagulant hormone levels in certain risk situations.

Key words

Prolactin - Leptin - Platelets - Venous thrombosis - Atherosclerosis

References

  • 1 Prandoni P, Bilora F, Marchiori A, Bernardi E, Petrobelli F, Lensing A W, Prins M H, Girolami A. An association between atherosclerosis and venous thrombosis.  N Engl J Med.. 2003;  348 1435-1441
    CrossrefPubMedGoogle Scholar
  • 2 Foley P W, Irvine C D, Standen G R. et al . Activated protein C resistance, factor V Leiden and peripheral vascular disease.  Cardiovasc Surg. 1997;  5 157-160
    PubMedGoogle Scholar
  • 3 Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients.  Blood Coagul Fibrinolysis. 1999;  10 251-259
    PubMedGoogle Scholar
  • 4 Marder V J, Matei D E. Hereditary and acquired thrombophilic syndromes. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis: basic principles & clinical practice. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2000 (Foley PW, 1997): 1243-1276
    Google Scholar
  • 5 Libby P, Simon D I. Thrombosis and atherosclerosis. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds) Hemostasis and thrombosis: basic principles & clinical practice. 4th ed. Philadelphia; Lippincott Williams & Wilkins 2000: 743-752
    Google Scholar
  • 6 Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques.  Clin Cardiol. 2000;  23 (Suppl 6) VI-3
    PubMedGoogle Scholar
  • 7 Sueishi K, Ichikawa K, Kato K, Nakagawa K, Chen Y X. Atherosclerosis: coagulation and fibrinolysis.  Semin Thromb Hemost. 1998;  24 255-260
    PubMedGoogle Scholar
  • 8 Holvoet P, Collen D. Thrombosis and atherosclerosis.  Curr Opin Lipidol. 1997;  8 320-328
    PubMedGoogle Scholar
  • 9 FitzGerald G A, Tigges J, Barry P, Lawson J A. Markers of platelet activation and oxidant stress in atherothrombotic disease.  Thromb Haemost. 1997;  78 280-284
    PubMedGoogle Scholar
  • 10 Drouet L, Mazoyer E, Bal dit Sollier C, Hainaud P, Ripoll L. Participation des mécanismes de la thrombose et de l’hémostase aux étapes initiales de l’athérosclérose.  Arch Mal Coeur Vaiss. 1998;  91 41-51
    PubMedGoogle Scholar
  • 11 Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study.  Arterioscler Thromb Vasc Biol. 2001;  21 1701-1705
    CrossrefPubMedGoogle Scholar
  • 12 Ruggeri Z M. Platelets in atherothrombosis.  Nat Med. 2002;  8 1227-1234
    CrossrefPubMedGoogle Scholar
  • 13 Celi A, Lorenzet R, Furie B, Furie B C. Platelet-leukocyte-endothelial cell interaction on the blood vessel wall.  Semin Hematol. 1997;  34 327-335
    PubMedGoogle Scholar
  • 14 Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates.  Circulation. 2000;  102 1931-1936
    PubMedGoogle Scholar
  • 15  . Pulmonary Embolism Prevention trial Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial.  Lancet. 2000;  355 1295-1302
    CrossrefPubMedGoogle Scholar
  • 16 Collins R, Baigent C, Sandercock P, Peto R. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials.  Antiplatelet Trialists’ Collaboration. BMJ. 1994;  309 1215-1217
    PubMedGoogle Scholar
  • 17  . Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Antiplatelet Trialists’ Collaboration.  BMJ. 1994;  308 235-246
    Google Scholar
  • 18 Toglia M R, Weg J G. Venous thromboembolism during pregnancy.  N Engl J Med. 1996;  335 108-114
    CrossrefPubMedGoogle Scholar
  • 19 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet. 1999;  353 1158-1165
    CrossrefPubMedGoogle Scholar
  • 20 Rosendaal F R. Risk factors for venous thrombotic disease.  Thromb Haemost. 1999;  82 610-619
    PubMedGoogle Scholar
  • 21 Dahlback B. Blood coagulation.  Lancet. 2000;  355 1627-1632
    CrossrefPubMedGoogle Scholar
  • 22 Dardenne M, de Moraes M, Kelly P A, Gagnerault M C. Prolactin receptor expression in human hematopoietic tissues analyzed by flow cytofluorometry.  Endocrinology. 1994;  134 2018-2114
    CrossrefPubMedGoogle Scholar
  • 23 Corash L. Measurement of platelet activation by fluorescence-activated flow cytometry.  Blood Cells. 1990;  16 97-106
    PubMedGoogle Scholar
  • 24 Wallaschofski H, Donne M, Eigenthaler M, Hentschel B, Faber R, Stepan H, Koksch M, Lohmann T. PRL as a novel potent cofactor for platelet aggregation.  J Clin Endocrinol Metab. 2001;  86 5912-5919
    CrossrefPubMedGoogle Scholar
  • 25 Zornberg G I, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thrombembolism: a case-control study.  Lancet. 1999;  356 1219-1223
    PubMedGoogle Scholar
  • 26 Wallaschofski H, Eigenthaler M, Kiefer M, Manfred D, Hentschel B, Gertz H J, Lohmann T. Hyperprolactinemia in patients on antipsychotic drugs causes ADP stimulated platelet activation that might explain the increased risk for venous thromboembolism.  In press
    Google Scholar
  • 27 Wallaschofski H, Kobsar A, Siegemund A, Sokolova O, Hentschel B, Tuschy U, Lohmann T, Eigenthaler M. Prolactin Receptor Signaling during Platelet Activation.  M Horm Metab Res.. 2003;  35 228-235
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor.  Diabetes. 1999;  48 426-429
    CrossrefPubMedGoogle Scholar
  • 29 Konstantinidis S, Schäfer K, Koschnick S, Loskutoff D J. Leptin-dependent platelet aggregation and arterial thrombosis suggest a mechanism for atherothrombotic disease in obesity.  J Clin Invest. 2001;  108 1533-1540
    CrossrefPubMedGoogle Scholar
  • 30 Maruyama I, Nakata M, Yamaji K. Effect of leptin in platelet and endothelial cells. Obesity and arterial thrombosis.  Ann N Y Acad Sci. 2000;  902 315-319
    PubMedGoogle Scholar
  • 31 Printen K J, Miller E V, Mason E E, Barnes R W. Venous thromboembolism in the morbidly obese.  Surg Gynecol Obstet. 1978;  147 63-64
    PubMedGoogle Scholar
  • 32 Konstantinides S, Schafer K, Loskutoff D J. The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity.  Ann N Y Acad Sci Dec. 2001;  947 134-141; discussion 141 - 142
    PubMedGoogle Scholar
  • 33 Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir I C, Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency.  Obesity Research. 2001;  9 627-630
    CrossrefPubMedGoogle Scholar
  • 34 Bodary P F, Westrick R J, Wickenheiser K J, Shen Y, Eitzman D T. Effect of leptin on arterial thrombosis following vascular injury in mice.  JAMA. 2002;  287 1706-1709
    CrossrefPubMedGoogle Scholar
  • 35 Pirisi A. Leptin linked to blood clots in obesity.  Lancet. 2002;  359 1215
    PubMedGoogle Scholar
  • 36 Wallaschofski H, Kobsar A, Sokolova O, Stepan H, Faber R, Siegemund A, Eigenthaler M, Lohmann T. Differences in platelet activation by prolactin and leptin.  Submitted
    Google Scholar
  • 37 Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.  Clin Endocrinol (Oxf). 1998;  48 547-553
    CrossrefPubMedGoogle Scholar
  • 38 Considine R V, Sinha M K, Heiman M L, Kriaciunas A, Stephens T W, Nyce M R, Ohanessian J P, Marco C C, McKee L J, Bauer T R, Caro T R. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl.  J Med. 1996;  334 292-295
    CrossrefPubMedGoogle Scholar
  • 39 Maffei M. et al . Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.  Nat Med. 1995;  1 1155-1161
    CrossrefPubMedGoogle Scholar
  • 40 Friedman J M, Halaas J L. Leptin and the regulation of body weight in mammals.  Nature. 1998;  395 763-770
    CrossrefPubMedGoogle Scholar
  • 41 Boyar R M, Finkelstein J W, Kapen S, Hellman L. Twenty-four hour prolactin (PRL) secretory patterns during pregnancy.  J Clin Endocrinol Metab. 1975;  40 1117-1120
    PubMedGoogle Scholar
  • 42 Sagawa N, Yura S, Itoh H, Mise H, Kakui K, Korita D, Takemura M, Nuamah M A, Ogawa Y, Masuzaki H, Nakao K, Fujii S. Role of leptin in pregnancy, a review.  Placenta. 2002;  23 (Suppl A) S80-86
    CrossrefPubMedGoogle Scholar
  • 43 Wauters M, Considine R V, Van Gaal L F. Human leptin: from an adipocyte hormone to an endocrine mediator.  Eur J Endocrinol. 2000;  143 293-311
    CrossrefPubMedGoogle Scholar
  • 44 Wieck A, Haddad P M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.  Br J Psychiatry. 2003;  182 199-204
    CrossrefPubMedGoogle Scholar
  • 45 Herran A, Garcia-Unzueta M T, Amado J A, de La Maza M T, Alvarez C, Vazquez-Barquero J L. Effects of long-term treatment with antipsychotics on serum leptin levels.  Br J Psychiatry. 2001;  179 59-62
    CrossrefPubMedGoogle Scholar
  • 46 Ross R. Atherosclerosis - an inflammatory disease.  N Engl J Med. 1999;  340 115-126
    CrossrefPubMedGoogle Scholar
  • 47 Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis.  J Leukoc Biol. 2000;  68 437-446
    CrossrefPubMedGoogle Scholar
  • 48 Walker S E, Yu-Lee L-Y. Overview: prolactin and autoimmunity.  Lupus. 2001;  10 669
    PubMedGoogle Scholar
  • 49 Goffin V, Binart N, Touraine P, Kelly P A. Prolactin: The new biology of an old hormone.  Annu Rev Physiol. 2002;  64 47-67
    CrossrefPubMedGoogle Scholar
  • 50 Soderberg S, Ahren B, Stegmayr B, Johnson O, Wiklund P G, Weinehall L, Hallmans G, Olsson T. Leptin is a risk marker for first-ever hemorrhagic stroke in a population-based cohort.  Stroke. 1999;  30 328-337
    PubMedGoogle Scholar

H. Wallaschofski,M. D. 

Dept. of Internal Medicine I · University of Erlangen

Ulmenweg 18 · 91054 Erlangen · Germany

Phone: + 49 (9131) 85 35230

Fax: + 49 (9131) 85 35231 ·

Email: Henri.Wallaschofski@med1.imed.uni-erlangen.de

      >